SAN DIEGO, CA--(Marketwire - February 11, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) is
applying for a grant offered jointly between the National Cancer Institute
(NCI) and the National Institute on Aging (NIA). Both NCI and NIA are part
of the National Institutes of Health. The grant Entest is applying for
will involve studying cancer stem cells, specifically looking for
characteristics among cancer stem cells leading to chemotherapy resistance.
If approved, Entest could receive up to $500,000 in funding over a two year
period. This research dovetails into Entest's immunotherapeutic cancer
vaccine model, as immunotherapy could prove significant in overcoming
chemotherapy resistance in tumor cells.
Entest's Chairman & CEO David Koos noted, "We are interested in isolating
cancer stem cells, which are characteristically resistant to
chemotherapeutic agents. By isolating these cancer stem cells, we believe
a cancer vaccine can be produced with a high efficacy level."
Currently, the Company's researchers are examining animal tumors. This
research coupled with the immunotherapeutic research in process should
assist the Company in rapidly moving forward with the development of a more
efficacious treatment for cancer tumors.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of
stem cell therapy treatments for Chronic Obstructive Pulmonary Disease
(COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell
research applications for diabetes and other illnesses. The Company also is
involved with medical device development (including stem cell extraction
instrumentation). ENT - 576 is a proprietary laser device currently under
development by Entest. The Company has filed 3 patent applications
relating to the treatment of COPD.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of
Entest BioMedical Inc. BMSN is a biotechnology company headquartered in
San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure
cryogenic stem cell banks, three research laboratories, aseptic
cellular/tissue class 10,000/100 processing lab, hematology, microbiology
and flow cytometry laboratories. David Koos serves as Chairman & CEO
concurrently for BMSN and ENTB.
This news release may contain forward-looking statements. Forward-looking
statements are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to which
forward-looking statements are subject include, but are not limited to, the
effect of government regulation, competition and other material risks.